ABSI Share Price Performance
US$3.38
-0.54 (-13.78%)
Price US$3.38
Share PriceUS$3.38
Absci Corporation Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 50 Fair Values set on narratives written by author
ABSI Community Narratives
There are no narratives available yet.
Absci Corporation Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.76
- Gross Margin
- -1,634.75%
- Net Profit Margin
- -2,737.94%
- Debt/Equity Ratio
- 1.2%
Absci Corporation Competitors
Snowflake Analysis
About ABSI
- Founded
- 2011
- Employees
- 157
- CEO
- WebsiteView website
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design differentiated antibody therapeutics. Its preclinical development programs include ABS-101 for the treatment of inflammatory bowel disease; ABS-201 for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
U.S. Market Performance
- 7 Days: 0.9%
- 3 Months: 8.7%
- 1 Year: 18.4%
- Year to Date: 14.8%
Over the last 7 days, the market has remained flat, although notably the Healthcare sector gained 6.4% in that time. More promisingly, the market is up 18% over the past year. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›